Clinical Trial Update: Pilot Study of PD-1inhibitor (Tislelizumab) Plus Chemotherapy as Neoadjuvant Therapy for Limited-Stage Small-Cell Lung Cancer [Phase 2]

View source ↗

Summary

Phase 2 pilot study evaluating tislelizumab (PD-1 inhibitor) plus chemotherapy as neoadjuvant therapy for limited-stage small-cell lung cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Small Cell Lung Cancer

Drugs mentioned

• Tislelizumab (tislelizumab)

Snippet

Sponsor: Shanghai Pulmonary Hospital, Shanghai, China | Conditions: Small-cell Lung Cancer | Phase 2 | Status: UNKNOWN